- Home
- KOD vs SLRC Comparison
KOD vs SLRC Comparison
Compare KOD & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | SLRC |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | 121 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 803.0M |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | KOD | SLRC |
|---|---|---|
| Price | $23.19 | $13.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $28.29 | $15.58 |
| AVG Volume (30 Days) | ★ 503.1K | 308.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.53% |
| EPS Growth | ★ 32.60 | N/A |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $13.64 |
| 52 Week High | $31.18 | $17.26 |
Technical Indicators
Market Signals| Indicator | KOD | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 32.05 |
| Support Level | $21.19 | N/A |
| Resistance Level | $29.17 | $15.52 |
| Average True Range (ATR) | 1.70 | 0.38 |
| MACD | -0.35 | -0.07 |
| Stochastic Oscillator | 8.59 | 0.00 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.